吉西他滨联合放疗治疗老年晚期非小细胞肺癌近期疗效研究  

Recent efficacy study of gemcitabine combined with radiotherapy in the treatment of elderly patients with advanced non-small cell lung cancer

作　　者：高丽敏[1] 沈慧敏[1] 

机构地区：[1]中国医科大学附属盛京医院第一胸外科,沈阳110004

出　　处：《实用药物与临床》2015年第3期341-344,共4页Practical Pharmacy and Clinical Remedies

摘　　要：目的探讨吉西他滨(GEM)联合放疗治疗老年晚期非小细胞肺癌的近期疗效及安全性。方法收集2012年3月至2015年1月来我院就诊的老年晚期非小细胞肺癌患者92例,将患者随机分为研究组和对照组,每组46例。对照组采用三维适形放疗,放疗剂量为60~70 Gy/6~7周。研究组采用GP方案(吉西他滨+顺铂)及三维适形放疗:GEM 1 g/m2,静脉滴注dl、8;顺铂(DDP)30 mg/m2,静脉滴注,d1~d3。3~4周为1个疗程,化疗时间不低于2个周期。比较两组总有效率、生活质量改善程度及不良反应发生情况。结果研究组46例,CR 7例,PR 28例,SD 9例,PD 2例,总有效率为76.06%;对照组46例,CR 3例,PR 19例,SD 16例,PD 8例,总有效率为47.82%。研究组总有效率明显高于对照组(P<0.05)。两组患者生活质量改善情况比较:研究组KPS评分改善36例,稳定14例,下降2例,改善率为65.21%;对照组KPS评分改善21例,稳定16例,下降9例,改善率为45.65%。两组生活质量改善情况比较差异有统计学意义(P<0.05)。研究组不良反应发生率明显高于对照组,两组比较差异具有统计学意义(P<0.05)。结论吉西他滨联合放疗治疗老年晚期非小细胞肺癌患者近期疗效确切,可提高临床疗效,改善患者生活质量,虽然不良反应发生率稍有提高,但患者可耐受。Objective To discuss the recent efficacy and safety of gemcitabine combined with radiotherapy on elderly patients with advanced non-small cell lung cancer.Methods 92 cases of the elderly patients with advanced non-small cell lung cancers from March 2012 to January 2015 in our hospital and were randomly divided into study group and control group,46 cases in each group.Control group used three-dimensional conformal radiotherapy,radiotherapy dose was 60 -70 Gy / 6-7 weeks.Study group was treated with GP scheme（gemcitabine ＋ cisplatin） combined with three-dimensional conformal radiotherapy：gemcitabine（GEM） 1 g/m,intravenously,d1,8;cisplatin（DDP） 30 mg/m^2,intravenously,d1 ~ d3.The circle of chemotherapy was 3 or 4 weeks,lasting for more than 2 cycles.The total efficiency,improvement in the quality of life and adverse reactions of the two groups were compared.Results There were 7 cases of CR,28 cases of PR,9 cases of SD and 2 cases of PD in study group,the total effective rate was 76.06%;in control group,there were 3 cases of CR,19 cases of PR,16 cases of SD and 8 cases of PD,the total effective rate was 47.82%.The total effective rate of study group was higher than that of control group,there was significant difference（P 0.05）.The improvement rate KPS score of study groupwas higher than that of control group（65.21%vs.45.65%）,there was significant difference（P 0.05）.The incidence of adverse reactions of study group was significantly higher than that of control group,there was significant difference between the two groups（P 0.05）.Conclusion Gemcitabine combined with radiotherapy for elderly patients with advanced nonsmall cell lung cancer can improve the recent clinical efficacy and the quality of life,the patient can tolerate the adverse reactions,though the incidence of the combination therapy is slightly higher than radiotherapy.

关 键 词：非小细胞肺癌 吉西他滨 化疗 老年患者 

分 类 号：R734.2[医药卫生—肿瘤]